Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.

导出 OA

翻译打印收藏纠错

作者： Amira A,Barkal ^[1] ; Kipp,Weiskopf ^[1] ; Kevin S,Kao ^[2] ; Sydney R,Gordon ^[1] ; Benyamin,Rosental ^[1] ; Ying Y,Yiu ^[1] ; Benson M,George ^[1] ; Maxim,Markovic ^[1] ; Nan G,Ring ^[1] ; Jonathan M,Tsai ^[1] ; Kelly M,McKenna ^[1] ; Po Yi,Ho ^[1] ; Robin Z,Cheng ^[1] ; James Y,Chen ^[1] ; Layla J,Barkal ^[1] ; Aaron M,Ring ^[3] ; Irving L,Weissman ^[4] ; Roy L,Maute ^[5]

作者单位： Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. ^[1] Brigham and Women's Hospital, Boston, MA, USA. ^[2] Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA. ^[3] Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. ^[4] Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. irv@stanford.edu. ^[5] Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford, CA, USA. irv@stanford.edu. ^[6] Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. irv@stanford.edu. ^[7] Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. irv@stanford.edu. ^[8] Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. rmaute@stanford.edu. ^[9] Ab Initio Biotherapeutics, South San Francisco, CA, USA. rmaute@stanford.edu. ^[10]